Cargando…
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
AIMS: Sodium glucose co‐transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some have reported risk of below‐knee lower extremity (BKLE) amputation. This study examined the real‐world comparative effe...
Autores principales: | Ryan, Patrick B., Buse, John B., Schuemie, Martijn J., DeFalco, Frank, Yuan, Zhong, Stang, Paul E., Berlin, Jesse A., Rosenthal, Norman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220807/ https://www.ncbi.nlm.nih.gov/pubmed/29938883 http://dx.doi.org/10.1111/dom.13424 |
Ejemplares similares
-
Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study
por: Yuan, Zhong, et al.
Publicado: (2017) -
Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
por: Haas, B, et al.
Publicado: (2014) -
Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014) -
SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019) -
Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
por: Kellon, Eleanor M., et al.
Publicado: (2022)